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Abstract
Background: The use of liposomes as drug delivery systems is the most promising technique for targeting drug
especially for anticancer therapy.
Methods: In this study sterically stabilized liposomes was prepared from DPPC/Cholesterol/PEG-PE encapsulated
doxorubicin. The effect of lyophilization on liposomal stability and hence expiration date were studied. Moreover,
the effect of diode laser on the drug released from liposomesin vitro and in vivo in mice carrying implanted solid
tumor were also studied.
Results: The results indicated that lyophilization of the prepared liposomes encapsulating doxorubicin led to
marked stability when stored at 5 °C and it is possible to use the re-hydrated lyophilized liposomes within 12 days
post reconstitution. Moreover, the use of low energy diode laser for targeting anticancer drug to the tumor cells is
a promising method in cancer therapy.
Conclusion: We can conclude that lyophilization of the liposomes encapsulating doxorubicin lead to marked
stability for the liposomes when stored at 5°C. Moreover, the use of low energy diode laser for targeting anticancer
drug to the tumor cells through the use of photosensitive sterically stabilized liposomes loaded with doxorubicin is
a promising method. It proved to be applicable and successful for treatment of Ehrlich solid tumors implanted in
mice and eliminated toxic side effects of doxorubicin.
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Background
Targeting drugs through carrier system have been a prom-
ising theme in therapeutics research. It is usually attained
by utilizing a carrier e.g., albumin conjugates, antibodies,
lectine, glycoproteins, DNA, dextran, polysaccharides,
nanoparticles and liposomes [1–6]. There is widespread
interest of using liposomes as drug carriers, which re-
quires pharmaceutically acceptable procedures for scaling
up to larger batch sizes, stable and economically feasible.
Liposomes can be defined as vesicles in which an aqueous
phase is entirely enclosed by one or several membranes com-
posed of phospholipid molecules. It can be constructed to
entrap quantities of materials within their aqueous
compartment and/or within the membranes [7–12]. Lipo-
somes have been widely studied in medically-related fields as
capsules for in vivo delivery of therapeutic agents [5, 13–15].
Since liposomes are used as carrier vehicles for anticancer
drugs [6, 16], it is better to target the drug to the site of ac-
tion, enhance and sustain its clinical effects, reduce its tox-
icity and protect it from metabolism and immune responses
[15, 17, 18].
There are four main strategies to target drugs encapsulated
liposomes. These strategies include antibody - coated lipo-
somes which are specifically bound to antigen - presenting
target cells. These liposomes facilitate the uptake by macro-
phage [19]. Thermosensitive liposomes, which are undergo-
ing phase transition at a specific temperature, are able to
release their content at a desirable temperature since the per-
meability of liposomal membrane increases drastically at its
phase transition [20]. When the target is warmed, liposomes
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release their drug content as they pass through the site
[21]. The third strategy is the use of pH-sensitive lipo-
somes where their membranes are stabilized by the
addition of a specific materials, such as fatty acids, which
are charged at neutral pH but lose their charge at low pH
destabilizing the vesicles [22]. Sensitive pH liposomes can
fuse with biomembrane and/or destabilize at low pH. The
fourth strategy depends on the fact that liposomes can be
stabilized by the presence of proteins, typically by anchor-
ing a specific antibody in the membrane through covalent
attachment of fatty acid chains or other lipid molecules.
When these legends aggregate by binding to the target,
their ability to stabilize the membrane is reduced and li-
posomes disintegrate releasing their content [23–25].
Doxorubicin (DOX) is one of the most valuable anti-
cancer drugs in the present clinical use. The use of DOX
within liposomes markedly reduces its cardio toxicity
without loss of its anticancer activity [15].
The aim of this study is to investigate the effect of
non-thermal laser dose on the drug release mechanism
from liposomes in-vitro and in- vivo studies.
Methods
Materials
1,2 dipalmitoyl-sn-phosphatidylecholine (DPPC) of molecu-
lar weight 743, Cholesterol (CHOL) of molecular weight
386.7, Lactose monohydrate and HEPS buffer, N-(2-Hy-
droxyl) peperazine-N-(2-ethanosulphonic acid), were pur-
chased from Sigma Chemicals St. Louis, USA. Distearyl-
phosphatidyl ethanolamine derivative at the amino pos-
ition with a molecular weight 2000 segment of polyethyl-
ene glycol (PEG-PE) was obtained from Liposome
Technology (LTI) USA. Doxorubicin hydrochloride
(DOX) was purchased in 10 mg - vial as freeze dried pow-
der from Farmitalia Research Laboratories, Milano, Italy.
Ammonium sulfate of purity 98 % was obtained from El
Nasr Chemical Company, Egypt. Sephadex G-75 superfine
purchased from Pharmacia Fine Chemicals, with beads
particle size 25–100 μm (The gel column was of 2.0 cm in
diameter and 30 cm in height). All chemicals were used
without further purification.
Methods
Liposomes preparation and drug encapsulation
In this work, sterically stabilized liposomes (stealth) were
prepared from DPPC/Chol/PEG-PE at the molar ratios
100:20:4, respectively. The lipids were dissolved in
chloroform and then deposited from organic solvent in a
thin film on the walls of the round bottom flask of the
rotary evaporator under reduced pressure and nitrogen
gas. Ammonium sulfate (250 mM at pH 4) was then
added to hydrate the dried thin film in the flask and kept
in the water bath at 55 °C for hydration. To get small
vesicles, the suspension is sonicated under temperature
control for a period of 2 h. The sample was then gently
poured on a surface of the gel chromatographic column
packed with sephadex G-75 for the removal of un-
entrapped ammonium sulfate.
Doxorubicin Hydrochloride (DOX) of 10 mg was dis-
solved in 5 ml HEPS buffer at pH 7.4and then added to
the liposome suspension that eluted from the gel column
at a concentration of 1 mg DOX/10 mol. of phospho-
lipid. The liposomes - DOX mixture was incubated in
water bath of a rotary evaporator for 1 h at 55 °C under
reduced pressure. Post incubation period, the sample
was passed again in the gel column to remove non-
encapsulated DOX. The drug loading took place by the
pH gradient method [26].
Liposomes lyophilization and characterization
The lyophilization process was taken through the use of
a freeze-drying system type Lyph-lock® 4.5 l manufac-
tured by Labconco Corporation USA. The prepared lipo-
somes encapsulating Dox were centrifuged for 15 min at
10,000 rpm and temperature of 15 °C. Liposomes pellet
was then added to 10 % lactose monohydrate solution
which protects liposomes against fusion and leakage
during lyophilization process [27, 28]. Liposomes sus-
pension was introduced into 2 ml- vials at a concentra-
tion 83 μg/ml. The vials were then freeze at −70 °C
before being attached to the freeze drying system. The
samples in the vials were then left for 24 h in the freeze
dryer till a dry cake was formed. Characterizations of the
lyophilized liposomes were carried out by measuring the
following parameters:
Size distribution Freshly prepared slides of the loaded
liposomes were scanned through the use of image
analyzer type SMAICA Systems with Ziess AXIOTRON
microscope (ELBEK GmbH, Germany). In this system,
the liposomes slides were imaged microscopically
through the use of an electronic camera which generates
an electronic signal proportional to the intensity of illu-
mination. Consequently, the full measurements of the
size and size distribution of the examined liposomes can
be recorded.
Drug release The drug release from the lyophilized lipo-
somes in buffer was studied.
Two milliliter of HEPS buffer was added to a vial contain-
ing lyophilized liposomes. The vials were centrifuged at
10,000 rpm for 15 min at −20 °C. So the supernatant was
sucked out.
The drug absorbance (A)in the supernatant was mea-
sured using a spectrophotometer (Shimatzu 1601PC,
Japan) at the characteristic absorption band of doxorubi-
cin (500 nm). So, the drug concentration, [Drug] was
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calculated using an experimental standard calibration
curve which is represented by the equation:
½Drug ¼ 58:5A0:82 ð1Þ
The sample was then incubated at 37 °C and the
amount of drug released was calculated after different
incubation periods up to 24 h.
Liposomes stability Lyophilized and unlyophilized lipo-
somes were stored on at 5 °C for periods up to
12 months. The following examinations were carried out
on the shelf stored liposomes every 2 months:
Size: The liposomes size was periodically examined
through the use of the image analyzer and its average
size was estimated.
Release and expiratory date: The concentration of the
encapsulated drug was measured as a function of the
storage time. So the expiratory date of the constructed
liposomes shelf-life (T90) for lyophilized and unlyophi-
lized liposomes was calculated.
Effect of laser on drug release
Diode laser of 250 mW and 650 nm continuous wave
(CW), Type DC BRUSHLESS PAT.PENDING Corp.,
Japan, was used. The deposited energy in Joules from
the CW laser was calculated from the equation:
EnergyðJÞ ¼ LaserpowerðJ=sÞ  exposuretimeðsÞ
In-vitro studies The drug release rate from lyophilized
liposomes was studied before and after exposure to dif-
ferent laser energies deposited in the sample. To follow
the release, 2 ml of saline were added to a vial contain-
ing lyophilized liposomes. The sample was then exposed
to laser for different exposure periods (i.e., different de-
posited energies). It is worthy to say that there was no
measurable temperature increase of the exposed lipo-
somes during laser irradiation. The absorbance of the
sample was then measured as a function of irradiation
dose at 37 °C, considering the value of the absorbance of
the sample before irradiation with laser as reference (i.e.,
zero level).
In-vivo studies Forty male BALB/C mice with average
weight 18 ± 2.0 g were used. The mice were inoculated
subcutaneously into the left flank with 1 × 106 single cell
suspension isolated from Ehrlich ascites carcinomas. An-
imals injected with tumor cells were classified into four
groups namely A, B, C and D, each was of 10 animals.
They undertake for the following protocol:
Group A: control group which didn’t receive any drug
or external treatment.
Group B: received a single dose of free doxorubicin
(DOX) of 2 μg/g of animal body weight (~40 μg DOX)
injected intraperitoneally at the7thday post tumor
implantation.
Group C: received a single dose of about 40 μg
doxorubicin encapsulated sterically stabilized liposomes
suspension injected intraperitoneally at the 7th day
post tumor implantation in the animal.
Group D: received the same amount of drug
encapsulated liposomes as groups C injected
intraperitoneally and treated by CW diode laser
(250 mW power and 75 J energy deposited) after one
hour post injection.
Tumor studies included
Tumor growth and survival period Tumor growth was
followed by measuring the three mutually orthogonal
tumor diameters with a caliper. The volume of the
tumor (V) was calculated from the tumor dimensions,
length a, width b and height c, which is given by the fol-
lowing equation [15]:
V ¼ π abcð Þ=6 ð2Þ
The tumor size was measured three times weekly
starting after the 7thday post tumor implantation. The
day of death of each mouse from each group was re-
corded and the percentage of surviving animals was cal-
culated. Experiment was terminated 90 days after tumor
implantation.
Histological examination Thirty five days after tumor
implantation part of the mice from groups A and B was
sacrificed and biopsies were performed. Tumors from
groups C and D were examined just before animal death
with 1 or 2 days. Tumors were excised and pathologically
examined using light microscope attached with camera.
Statistical analysis
The statistical methods and analysis for evaluation of the
results were done by calculating arithmetic means and
standard deviations for all groups. The Mann-Whitney
U-test was used to determine the significant differences
among values of different groups. A P < 0.05 was consid-
ered significant.
Animal ethics
All animal procedures and care were performed using
guidelines for the care and use of laboratory animal eth-
ics committee of King Saud University.
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Results and discussion
In-vitro studies
Characteristics of the lyophilized liposomes
Figure 1a, b represents photographs recorded by the
image analyzer system for the freshly prepared drug
loaded liposomes and the same liposomes after being
shelf stored at 5 °C for a period of one year respectively.
The results indicate that its average diameter is about
9.2 μm. Figure 2a, b shows images for the rehydrated ly-
ophilized liposomes and the same liposomes after being
shelf stored at 5 °C for a period of one year. Liposomal
size distribution indicated that there is no measurable
change in the form and diameter due to lyophilization
except the appearance of few clusters. Moreover, shelf
storage of the lyophilized liposomes didn’t cause meas-
urable change in their size.
The drug released from the lyophilized and unlyophi-
lized drug loaded sterically stabilized liposomes was
measured every 3 months after storage at 5 °C for pe-
riods up to 1 year.
Figure 3 illustrates the variation of the encapsulated drug
percentage in the lyophilized and unlyophilized liposomes
as a function of shelf storage period. The results indicate
that the expiratory date (T90) of the constructed lyophilized
Fig. 1 Photographs recorded by the image analyzer system for:
a Freshly prepared drug loaded liposomes and b The same liposomes
after being shelf stored at 5 °C for a period of one year
Fig. 2 Images for: a Rehydrated lyophilized liposomes and b The
same liposomes after being shelf stored at 5 °C for a period of one
year respectively
Fig. 3 Variation of the encapsulated drug percentage in the lyophilized
(red circle) and unlyophilized (black square) liposomes as a function
of shelf storage period. * Significant (p < 0.05) encapsulation drug
percentage compared to unlyophilized
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liposomes is 7.75 months and about 12 days for the unlyo-
philized liposomes. The values of the released and encapsu-
lated drug in the liposomes after incubation at 37 °C for
different periods up to 20 h is demonstrate in Table 1.
Effect of irradiation with continuous wave diode laser
Seven samples from the same vial were exposed to dif-
ferent deposited energies from the diode laser. Figure 4
shows the variation of the drug release concentration as
a function of laser energy deposited measured directly
after irradiation and 20 h post irradiation. The max-
imum release of the drug occurred at energy of 30 J.
Higher energies did not show considerable increase in
the amount of released drug. After liposomal exposure
to laser energy of 30 J, 33.6 % of the encapsulated drug
was released and it reached about 95 % after 20 h post
irradiation. This continuous release of drug after stop-
ping irradiation with laser can be explained as follows:
1. The drug loading methods used in the preparation
of sterically stabilized liposomes is the ammonium
sulfate gradient method. In this method, drug was
loaded due to its shuttle into the liposomes forming
complex gel of [(DOX)2 SO4]n in excess ammonium
sulfate.
2. These liposomes when irradiated with laser and
release amount of their encapsulated drugs, some of
the excess ammonium ions encapsulated in the
liposomes will be released and cause more leakage
from other liposomes [29].
3. This process propagates and enhances the drug
released from liposomes as far as ammonia ion
concentration in the medium is increased. A process
occurs as a feedback mechanism.
It may be presumed that irradiation with non-thermal
laser, results in activation of the liposomes, which will
result in the release of the drug from the irradiated lipo-
some. The release of excess ammonium sulfate ions
from the liposomes will in turn cause further release of
drug and ammonium sulfate from other liposomes.
Laser energy from the CW diode could work as a
powerful initiator for drug release and the ammonia re-
leased during the process is responsible for the delayed
drug release mechanism.
In-vivo studies
The tumor size was measured seven days post tumor
implantation in the animals. Figure 5 shows the variation
Table 1 Drug released from liposomes and drug encapsulated















0.0 0.0 69.4 100 0
0.5 2.5 ± 0.02a(S) 66.9 96.3 3.7
1.0 3.1 ± 0.02a(S) 66.3 95.5 4.5
3.0 3.2 ± 0.04a(S) 66.2 95.3 4.7
5.0 4.1 ± 0.03a(S) 65.3 94.1 5.91
7.0 5.8 ± 0.05a(S) 63.6 91.6 8.4
10.0 7.2 ± 0.05a(S) 62.2 89.6 10.4
20.0 7.7 ± 0.02a(S) 61.7 88.9 11.1
aCompared to control group, S Significant when p < 0.05, NS not
significant (P > 0.05)
Fig. 4 Variation of the drug release concentration as a function of
laser energy deposited measured directly after irradiation and 20 h
post irradiation. * Significant (p < 0.05) drug release concentration
measured 20 h post irradiation compared to measured directly
after irradiation
Fig. 5 Variation of the average tumor size with the incubation period
for all animals from the groups; A (control group), B (received a single
dose of free doxorubicin), C (received a single dose doxorubicin
encapsulated liposomes), and D (received as groups C injected and
treated by CW diode laser). * Significant (p < 0.05) increase in tumor
size for groups A, B & C. ** Not significant (P > 0.05) increase in tumor
size for group D from day 30 till the day 90
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of the average tumor size with the incubation period for
all animals from the groups A, B, C, and D. Injection of
the animals with free doxorubicin slightly inhibited
tumor growth (group B) as compared with group A. An-
imals from groups A and B did not survive more than
30 days post injection with the tumor. The tumor
growth in group C was much slower than that of groups
A and B. The animals in group C survived till the day 60
post injection with tumor. Therefore, the injection of
drug loaded liposomes has the advantage of protecting
the drug from metabolism and immune responses which
rendered it effective for longer period [17, 18]. More-
over, the toxic side effects of doxorubicin to sensitive or-
gans such as heart, bone marrow and erythrocyte
membrane may be reduced [26, 30, 32]. At the day of
animal death of group C, the average tumor size was
about 1.5 cm3 while at day of death of animals of groups
A and B the average tumor size was only 0.93 and
0.85 cm3 respectively.
For animals of group D, the tumor growth rate was
minimized as compared with animals from other groups
till day 30 post injection of the tumor in the animals. In-
significant increase of the tumor size occurred from the
day 30 till the day 90 when the animals were sacrificed
and plateau like dependence of the tumor size on the in-
cubation period is noticed.
Histological examination of samples took place at day 28
post tumor implantation for animals of groups A and B.
Therefore, the histological examination of the tumors of
group C was managed at day 60 and of group D at day 90.
Animals from group D were active similar to normal group
till day 90 when they were sacrificed. Figure 6 represents a
light microscope photograph for a histological section in a
tumor from animals of group A. It is clear that the neoplas-
tic cells with hyper chromatic and pleomorphic nuclei and
scant eosinophilic cytoplasm are arranged in sheets. These
neoplastic cells vary in size and shape. Histological section
for group B showed the presence of islands of aggregates of
neoplastic cells. These cells vary in size and shape. Islands
of normal subcutaneous tissue were seen between the ag-
gregates of tumor cells. Moreover, smaller islands of aggre-
gated neoplastic cells and there are islands of necrotic cells
are seen in the histological section of group C.
Figure 7 shows a photograph from a light microscope
for a histological section in the tumor of animals of
group D. It is clear from the figure that there is complete
cure of the aggregates of neoplastic cells with normal
subcutaneous tissue.
An important site of cytotoxic action of the anticancer
drug doxorubicin is the nucleus, where doxorubicin in-
tercalates into DNA, forming DNA adducts and inhibit-
ing topoisomerase II. When free doxorubicin reaches
the tumor site, doxorubicin that is released from lipo-
somes within the tumor interstitial space is capable of
diffusing widely within the tumor. Doxorubicin can dif-
fuse into surrounding cell membrane or protein associ-
ated, or diffuses into subcellular compartments such as
mitochondria and nuclei [14, 33].
The histological examination of the tumor from the
animals from groups A, B, C, and D proved that animals
injection with sterically stabilized liposomes loaded with
doxorubicin and targeted to the tumor by non-thermal
diode laser energy of 70 J in one shot during 5 min ad-
ministration gave complete curing of the tumor and no
further tumor growth was measured. Sixty percent of
the animals survived longer than day 100 post implant-
ation of the tumor. The death of the 40 % of the animals
before day 100 may be due to the flow of some tumor
cells in the blood stream (during injection process by
tumor cells) to other untreated organs with laser which
may lead to acceleration of animal death. These findings
are supported by a number of researches considering the
antitumor effectiveness of electrotherapy or electro-
chemotherapy [34–37].
Fig. 6 Light microscope photograph for a histological section in a
tumor from animals of group A
Fig. 7 Light microscope photograph for a histological section in
tumor of animals of group D
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DOX-loaded liposomes have enhanced efficacy in
some solid tumors compared with free doxorubicin, be-
cause they passively target solid tumors through the en-
hanced permeability and retention effect [38, 39],
resulting in increased drug payloads delivered to tumors.
The enhanced permeability and retention effect are a re-
sult of defective vascular endothelial linings of growing
tumors, resulting in gaps in the endothelium up to f800
nm in diameter, which are large enough to permit the
extravasation of liposomes with diameters in the range
of 100 nm [40]. In addition, growing tumors have
defective lymphatic drainage, which contributes to the
extended residence time of extravagated liposomes in
the interstitial space of the tumor. Liposomes residing in
the interstitial space gradually release their entrapped
drug, exerting antitumor effects.
Conclusion
We can conclude that lyophilization of the liposomes
encapsulating doxorubicin lead to marked stability for
the liposomes when stored at 5 °C. It is possible to use
rehydrated lyophilized liposomes within 12 h post rehy-
dration, in case of being stored at 5 °C. The size of the
tumor is not the only marker for the survival period of
the animal. The use of low energy diode laser for target-
ing anticancer drug to the tumor cells through the use
of photosensitive sterically stabilized liposomes from
DPPC-Chol-PEG-PE loaded with doxorubicin by the pH
ammonium sulfate technique is a promising method. It
proved to be applicable and successful for treatment of
Ehrlich solid tumors implanted in mice and eliminated
toxic side effects of doxorubicin.
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